Allogene Therapeutics (ALLO) Insider Trading & Ownership → A ‘DeFi Summer’ Projected! (From Crypto 101 Media) (Ad) Free ALLO Stock Alerts $3.01 +0.03 (+1.01%) (As of 05:32 PM ET) Add Compare Share Share Insider TradesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Allogene Therapeutics (NASDAQ:ALLO) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage24.30%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$684.00Number OfInsiders Selling(Last 12 Months)2Amount OfInsider Selling(Last 12 Months)$93,228.00 Get ALLO Insider Trade Alerts Want to know when executives and insiders are buying or selling Allogene Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address ALLO Insider Buying and Selling by Quarter Ad Manward PressThe most important AI company you've never heard ofBecause this small company solves the BIGGEST problem with Nvidia's AI chips. Already, Amazon, Microsoft, Google and others are lining up to get this company's products.Get the full story on this secret AI company poised for massive growth Allogene Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails1/30/2024Geoffrey M ParkerCFOBuy190$3.60$684.00 12/18/2023Deborah M MessemerDirectorSell18,640$2.70$50,328.00 8/7/2023Stephen MayoDirectorSell10,000$4.29$42,900.00 (Data available from 1/1/2013 forward) ALLO Insider Trading Activity - Frequently Asked Questions Who is on Allogene Therapeutics's Insider Roster? The list of insiders at Allogene Therapeutics includes Alison Moore, Arie Belldegrun, David D Chang, Deborah M Messemer, Eric Thomas Schmidt, Geoffrey M Parker, Owen N Witte, Rafael Amado, Stephen Mayo, and Veer Bhavnagri. Learn more on insiders at ALLO. What percentage of Allogene Therapeutics stock is owned by insiders? 24.30% of Allogene Therapeutics stock is owned by insiders. Learn more on ALLO's insider holdings. Which Allogene Therapeutics insiders have been buying company stock? The following insider purchased ALLO shares in the last 24 months: Geoffrey M Parker ($684.00). How much insider buying is happening at Allogene Therapeutics? Insiders have purchased a total of 190 ALLO shares in the last 24 months for a total of $684.00 bought. Which Allogene Therapeutics insiders have been selling company stock? The following insiders have sold ALLO shares in the last 24 months: Deborah M Messemer ($50,328.00), Owen N Witte ($282,600.00), Rafael Amado ($154,280.00), Stephen Mayo ($42,900.00), and Veer Bhavnagri ($83,853.06). How much insider selling is happening at Allogene Therapeutics? Insiders have sold a total of 77,742 Allogene Therapeutics shares in the last 24 months for a total of $613,961.06 sold. More Insider Trading Tools from MarketBeat Related Companies: Alector Insider Ownership ProKidney Insider Ownership Voyager Therapeutics Insider Ownership C4 Therapeutics Insider Ownership Editas Medicine Insider Ownership Taysha Gene Therapies Insider Ownership Adaptive Biotechnologies Insider Ownership Humacyte Insider Ownership iTeos Therapeutics Insider Ownership Lexeo Therapeutics Insider Ownership Insider Tracking Tools: CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country: U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles: 4 Small-Cap Energy Stocks Insiders are Buying 3 Penny Stocks That Insiders Are BuyingThe 3 Hottest Insiders Buys This Month 3 Companies Buying Back Cheap Stock LatelyPagaya Technologies: An AI Fintech That Insiders Are Buying This page (NASDAQ:ALLO) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportBiden to Drop BOMBSHELL June 13th?Paradigm PressElon to Transform U.S. Economy? Porter & CompanyCharles Payne Demystifies OptionsUnstoppable ProsperityThe most important AI company you've never heard ofManward PressThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyElon’s New Device is About to Shock the WorldInvestorPlaceUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allogene Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.